Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Piramal PharmaNSE:PPLPHARMA +1.94%50 5-Year Yield-on-Cost % is 0.07 as of Aug. 11, 2026, which is 17% above its 10-year median of 0.06. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 50/100 and a GF Value™ of ₹186.59 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 512 Drug Manufacturers companies, Piramal Pharma ranks worse than 97.66% on this metric.
Piramal Pharma's yield on cost for the quarter that ended in Jun. 2026 was 0.07.
The historical rank and industry rank for Piramal Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:PPLPHARMA'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.04 Med: 0.06 Max: 0.1
Current: 0.07
During the past 6 years, Piramal Pharma's highest Yield on Cost was 0.10. The lowest was 0.04. And the median was 0.06.
NSE:PPLPHARMA's 5-Year Yield-on-Cost % is ranked worse than 97.66% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.285
vs NSE:PPLPHARMA: 0.07
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Piramal Pharma 5-Year Yield-on-Cost % Related Terms
NSE:PPLPHARMA vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Piramal Pharma is calculated as
Piramal Pharma (NSE:PPLPHARMA) has a 5-Year Yield-on-Cost % of 0.07 as of Aug. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Piramal Pharma and its competitors. This is 17% above median its historical median of 0.06. Over the past decade, Piramal Pharma's 5-Year Yield-on-Cost % has ranged from 0.04 to 0.10. According to the industry distribution chart, Piramal Pharma ranks #500 out of 512 companies in the Drug Manufacturers industry, placing it in the top 97.7%.
Is Piramal Pharma's 5-Year Yield-on-Cost % too high?
Piramal Pharma's current 5-Year Yield-on-Cost % of 0.07 is 17% above median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.10. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Piramal Pharma's value of 0.07 is 96.9% below this industry median. Based on the distribution chart, Piramal Pharma ranks #500 out of 512 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Piramal Pharma has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #500 out of 512 companies for 5-Year Yield-on-Cost %. This places Piramal Pharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. Piramal Pharma's value of 0.07 is 96.9% below this benchmark. Historically, Piramal Pharma's own 5-Year Yield-on-Cost % has ranged from 0.04 to 0.10 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 2.29, Piramal Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current 5-Year Yield-on-Cost % of 0.07 is 96.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current 5-Year Yield-on-Cost % is 0.07, which is 17% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹186.59, compared to a current price of ₹213.61 — trading 14.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.07, which is 17% above median its 10-year median of 0.06 and 96.9% below the Drug Manufacturers industry median of 2.29. Piramal Pharma's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current 5-Year Yield-on-Cost % is 0.07 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹213.61 is trading 14.5% above its estimated GF Value™ of ₹186.59.
GuruFocus considers Piramal Pharma to be Modestly Overvalued.
Key valuation signals for NSE:PPLPHARMA:
5-Year Yield-on-Cost %: 0.07 (17% above median its 10-year median of 0.06)
GF Value™: ₹186.59 vs. price of ₹213.61 (14.5% above fair value)
Industry Position: 96.9% below the Drug Manufacturers median (#500 of 512)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
50GF Score
Get the complete analysis for NSE:PPLPHARMA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
